[New post] OIR: Shanghai Fosun Pharmaceutical Group

alanyeo posted: " Mitigating GPO impact with new drug sales ramp up • Excluding one-off gains, 1H21 net profit grew 20.4% yoy, with international operations contributing positively to group. • Covid-19 vaccine is progressing through regulatory process in China, alth" Respond to this post by replying above this line New post on Alpha Edge Investing OIR: Shanghai Fosun Pharmaceutical Group by alanyeo Mitigating GPO impact with new drug sales ramp up • Excluding one-off gains, 1H21 net profit grew 20.4% yoy, with international operations contributing positively to group. • Covid-19 vaccine is progressing through regulatory process in China, although regulatory approvals may see some delays due to ongoing evaluationstudies. • Constructive growth outlook maintained, supported by new […] Read more of this post alanyeo | August 26, 2021 at 11:39 am | Categories: Equities - Research Reports by Brokers/ Banks | URL: https://wp.me/p7fA1-3ia Comment    See all comments    Like Unsubscribe to no longer receive posts from Alpha Edge Investing. Change your email settings at Manage Subscriptions. Trouble clicking? Copy and paste this URL into your browser: http://alphaedgeinvesting.com/2021/08/26/oir-shanghai-fosun-pharmaceutical-group-2/ Thanks for flying with WordPress.com